|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
US9266891B2
(en)
*
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
MX366703B
(es)
|
2013-03-15 |
2019-07-22 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de la proteína bet.
|
|
AR096837A1
(es)
|
2013-07-08 |
2016-02-03 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de proteínas bet
|
|
WO2015014998A1
(en)
*
|
2013-08-01 |
2015-02-05 |
Oncoethix Sa |
Pharmaceutical formulation containing thienotriazolodiazepine compounds
|
|
WO2015018522A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
|
|
WO2015018520A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
|
|
WO2015018523A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
A novel bet-brd inhibitor for treatment of solid tumors
|
|
KR20160037201A
(ko)
*
|
2013-08-06 |
2016-04-05 |
온코에틱스 게엠베하 |
Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
|
|
CA2929652A1
(en)
|
2013-11-08 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
CN105960239A
(zh)
*
|
2013-11-27 |
2016-09-21 |
翁科埃斯克斯有限公司 |
利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
|
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
CA2936865A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
|
SG11201607108XA
(en)
|
2014-02-28 |
2016-09-29 |
Tensha Therapeutics Inc |
Treatment of conditions associated with hyperinsulinaemia
|
|
EA034972B1
(ru)
|
2014-04-23 |
2020-04-13 |
Инсайт Корпорейшн |
1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
|
|
JP2017514907A
(ja)
*
|
2014-05-02 |
2017-06-08 |
オンコエシックス ゲーエムベーハー |
チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
|
|
WO2015168587A1
(en)
*
|
2014-05-02 |
2015-11-05 |
Oncoethix Sa |
Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds
|
|
CN107073014A
(zh)
*
|
2014-05-02 |
2017-08-18 |
翁科埃斯克斯有限公司 |
利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法
|
|
WO2015169953A1
(en)
*
|
2014-05-08 |
2015-11-12 |
Oncoethix Gmbh |
Method of treating glioma using thienotriazolodiazepine compounds
|
|
CA2947970A1
(en)
*
|
2014-05-08 |
2015-11-12 |
Oncoethix Gmbh |
Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
|
|
EP3154549A1
(en)
|
2014-06-13 |
2017-04-19 |
Oncoethix GmbH |
Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
|
|
US9968620B2
(en)
*
|
2014-08-19 |
2018-05-15 |
Oncoethix Gmbh |
Methods of treating lymphoma using thienotriazolodiazepine compounds
|
|
CN107427524A
(zh)
*
|
2014-08-28 |
2017-12-01 |
翁科埃斯克斯有限公司 |
利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
|
|
US9527864B2
(en)
|
2014-09-15 |
2016-12-27 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
BR112017008714A2
(pt)
*
|
2014-10-27 |
2017-12-19 |
Tensha Therapeutics Inc |
inibidores de bromodomínio
|
|
EP3227276B1
(en)
|
2014-12-02 |
2021-09-01 |
Ignyta, Inc. |
Combinations for the treatment of neuroblastoma
|
|
US10683305B2
(en)
|
2015-04-27 |
2020-06-16 |
Concert Pharmaceuticals, Inc. |
Deuterated OTX-015
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
HK1256417A1
(zh)
|
2015-09-11 |
2019-09-20 |
达纳-法伯癌症研究所股份有限公司 |
氰基噻吩并三唑并二氮杂环庚三烯及其用途
|
|
TW201722966A
(zh)
|
2015-10-29 |
2017-07-01 |
英塞特公司 |
Bet蛋白質抑制劑之非晶固體形式
|
|
MX2018006499A
(es)
|
2015-11-25 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos.
|
|
BR112018012255A2
(pt)
|
2015-12-18 |
2018-12-04 |
Ignyta Inc |
método para tratar câncer
|
|
EP3192502A1
(en)
*
|
2016-01-15 |
2017-07-19 |
Sandoz Ag |
Pharmaceutical composition of selexipag
|
|
WO2017121806A1
(en)
*
|
2016-01-15 |
2017-07-20 |
Sandoz Ag |
Pharmaceutical composition of selexipag
|
|
KR102643344B1
(ko)
|
2016-06-20 |
2024-03-07 |
인사이트 코포레이션 |
Bet 저해제의 결정질 고체 형태
|
|
AU2018302170B2
(en)
|
2017-07-19 |
2024-02-29 |
Ignyta, Inc. |
Pharmaceutical compositions comprising entrectinib
|
|
CN111225662B
(zh)
*
|
2017-10-17 |
2022-11-22 |
伊尼塔公司 |
药物组合物和剂型
|
|
CN111629725A
(zh)
*
|
2018-01-25 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
急性骨髓性白血病的组合治疗
|
|
AU2020348783B2
(en)
|
2019-09-18 |
2026-04-16 |
Bristol-Myers Squibb Company |
Extended release dosage forms for Tyk2 inhibitors
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022034914A1
(ja)
*
|
2020-08-13 |
2022-02-17 |
カルナバイオサイエンス株式会社 |
易溶性固形製剤およびその製法
|
|
JP7777136B2
(ja)
*
|
2020-12-18 |
2025-11-27 |
デウン ファーマシューティカル カンパニー リミテッド |
１－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な経口投与用製剤
|
|
CN116098870B
(zh)
*
|
2023-04-10 |
2023-07-25 |
上海赛默罗生物科技有限公司 |
α5-GABAA受体调节剂的固体分散体及其制备方法
|